A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is an exploratory, prospective, randomized, active control, and open label clinical
trial to evaluate the efficacy and safety of 6-9 months treatment with the ultrashort PRS
Regimen V.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators:
Anhui Chest Hospital Fourth Taiyuan People's Hospital, China Ganzhou Fifth People's Hospital, China Huashan Hospital No.85 Hospital, Changning, Shanghai, China Shanghai Public Health Clinical Center Shanghai Pudong New Area Pulmonary Hospital, China Weifang Second People's Hospital, China Zhengzhou Sixth People's Hospital, China